Why Guardant Health, Inc. (GH) stock moved
Guardant Health, Inc. (GH) shares climbed 5.3% to $187.22 as of October 5, 2026, a significant gain from the prior close of $177.80. BestStocks flagged the session as a major change for GH. The move is tied to company news. Below, we break down what changed for GH, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
Guardant Health rose 4.7% on September 15, 2026, driven by a major insurance coverage expansion for its Shield colorectal cancer screening blood test and positive momentum from a healthcare conference presentation. The day before, the company announced that EviCore by Evernorth—a major utilization management platform—would cover Shield for colorectal cancer screening, a significant step toward broader adoption. On the session itself, Guardant presented at the Morgan Stanley Global Healthcare Conference, reinforcing investor confidence in its precision oncology portfolio.
What it means for Guardant Health, Inc. investors
For Guardant Health, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 5.3% price move on light volume. Weighing against that: Guardant Health, Inc. (GH) moved -5.00% from $155.87 to $148.07 on 2026-07-20; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $200.07, implying +6.9% upside from $187.22. BestStocks rates the overall signal quality low (56/100). With earnings roughly 23 days out, the next report is the most likely near-term test of the move.
GH price reaction
GH last traded at $187.22, up $9.42 (+5.30%) from the previous close of $177.80. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $157.38 and $187.22, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Guardant Health, Inc. (GH)
The consensus analyst price target on Guardant Health, Inc. (GH) is $200.07, 6.9% above the recent $187.22. Over the past 90 days analysts logged 0 upgrades, 17 maintains, and 0 downgrades. Here is how the bullish and bearish cases on GH line up.
The bullish case
- Wall Street's consensus price target of $200.07 implies +6.9% upside from $187.22.
- The Street's most bullish target is $225.00 (+20.2%).
- Material positive event.
- Strong 5.3% price move on light volume.
- Guardant Health, Inc. (GH) moved +5.07% from $156.17 to $164.08 on 2026-07-09.
The bearish case
- The most bearish analyst target is $180.00 (-3.9%).
- Guardant Health, Inc. (GH) moved -5.00% from $155.87 to $148.07 on 2026-07-20.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 5, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for GH
In-depth GH event analyses
Frequently asked questions about GH
Why did Guardant Health, Inc. (GH) stock move?
Guardant Health rose 4.7% on September 15, 2026, driven by a major insurance coverage expansion for its Shield colorectal cancer screening blood test and positive momentum from a healthcare conference presentation. The day before, the company announced that EviCore by Evernorth—a major utilization management platform—would cover Shield for colorectal cancer screening, a significant step toward broader adoption. On the session itself, Guardant presented at the Morgan Stanley Global Healthcare Conference, reinforcing investor confidence in its precision oncology portfolio.
How much did GH stock rise?
GH gained 5.30% ($9.42) versus the prior close of $177.80, last trading at $187.22 on 0.7× average volume.
When is Guardant Health, Inc.'s next earnings date?
GH's next earnings report is estimated for 2026-10-28 — about 23 days away.
What is the analyst price target for GH?
The consensus analyst price target for GH is $200.07, about 6.9% above the current $187.22. Over the past 90 days, analysts recorded 0 upgrades, 17 maintains, and 0 downgrades.
How BestStocks tracks GH
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for GH, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 5, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.